Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Mar
30
2015
Perspectives on the President’s Precision Medicine Initiative Foley & Lardner LLP
Mar
28
2015
Threshold Issues: IPR Not Derailed by Unidentified D/B/A Name or Prior ANDA Certification McDermott Will & Emery
Mar
28
2015
TMI: When Does Fitness Data Become Too Much of a Good Thing? Greenberg Traurig, LLP
Mar
28
2015
PhRMA's Objections to HSR Rule on Exclusive Licenses Face Skeptical Appellate Judges ArentFox Schiff LLP
Mar
27
2015
Strike Two – FDA Rejects Amgen’s Certification Petition for Biosimilar Applicants Sterne, Kessler, Goldstein & Fox P.L.L.C.
Mar
27
2015
Fourth Circuit Sustains Securities Fraud Claim Against Drug Manufacturer Katten
Mar
26
2015
European Food Safety Authority (EFSA) Grants Public Access to Data through Scientific “Data Warehouse” Covington & Burling LLP
Mar
26
2015
FDA Issues Draft Guidance on Use of Electronic Informed Consent in Clinical Trials McDermott Will & Emery
Mar
26
2015
Patent Term Adjustment In The Post-RCE Period -- Request for Continued Examination Foley & Lardner LLP
Mar
25
2015
Failure to Warn About Dangers of Off-Label Use of Medical Device Preempted Under Federal Law Varnum LLP
Mar
25
2015
Teva Pharmaceuticals: Is It Time to Rethink How You Will Argue Claim Construction? Dickinson Wright PLLC
Mar
25
2015
Increased FTC Enforcement as FDA Deregulates Low-Rish Health IT Devices Morgan, Lewis & Bockius LLP
Mar
25
2015
Northern District of California Judge Seeborg Opens the Door to Alternative Route to Challenge Patents on Biologics ArentFox Schiff LLP
Mar
25
2015
When on Antibiotics in Nursing Home or Hospital Watch for Diarrhea – It Could Be C-Diff Stark & Stark
Mar
24
2015
While FDA’s Proposed e-Cigarette Rule is Pending, FTC Mulls Enforcement Action Morgan, Lewis & Bockius LLP
Mar
24
2015
USPTO Myriad-Mayo Guidance Still Not At An Alpha Standard Schwegman, Lundberg & Woessner, P.A.
Mar
23
2015
FDA is Examining Device Risk Assessments in Postmarket Settings Covington & Burling LLP
Mar
23
2015
One More Hurdle Cleared – Amgen’s Preliminary Injunction Motion for Filgrastim is Denied Sterne, Kessler, Goldstein & Fox P.L.L.C.
Mar
23
2015
California Federal Judge Finds Biosimilar Patent Procedures Optional Foley & Lardner LLP
Mar
21
2015
District Court Rules Against Amgen’s Motion for Preliminary Injunction to Prevent Marketing of Sandoz’s Biosimilar Zarxio Mintz
Mar
19
2015
FDA Issues Revised Draft Guidance on Disclosures of Risk Information in Consumer-Friendly Print Advertisements and Promotional Labeling McDermott Will & Emery
Mar
19
2015
Enzo Biochem V. Applera Corp. – When “Words Can Hurt You” Schwegman, Lundberg & Woessner, P.A.
Mar
18
2015
Indiana Federal Court Denies Generic Drug Manufacturer’s Motion to Dismiss Hatch-Waxman Patent Infringement Action on Jurisdiction Grounds Mintz
Mar
17
2015
FDA Issues Final Guidance on Reprocessing of Medical Devices Morgan, Lewis & Bockius LLP
Mar
17
2015
SB 411 Passes West Virginia Senate re: Asbestos Exposure Dinsmore & Shohl LLP
Mar
17
2015
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2015
Cereal Killer: NAD Un-Sweetens Some of MOM’s Breakfast Cereal Claims Proskauer Rose LLP
Mar
16
2015
House And Senate Committees To Mark Up Budget Resolutions; How Will Congress Deal With The Sequester; Debt Limit Reached Squire Patton Boggs (US) LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins